Cibus Advances Rice Herbicide Program, Strengthens Balance Sheet
Event summary
- Cibus reported Q1 2026 revenue of $1.7M, up from $1.0M in Q1 2025, with net loss narrowing to $21.2M from $49.4M YoY.
- Raised $37.3M in gross proceeds from two public offerings in Q1 2026, bringing cash position to $30.3M as of March 31, 2026.
- Transferred gene-edited rice traits to Latin American partner Interoc in May 2026, advancing toward 2027 commercial launch.
- Rescheduled U.S. launch of herbicide-tolerant rice to 2029 due to regulatory delays with partner Albaugh.
- Appointed Thomas Urban, former CEO of CellFor, to Board of Directors in April 2026.
The big picture
Cibus' progress in its rice herbicide tolerance program and sustainable ingredients initiative comes amid global agricultural challenges, including fertilizer supply disruptions. The company's ability to leverage its gene-editing platform across multiple crops positions it to address critical productivity and sustainability challenges in the sector. With $30.3M in cash as of Q1 2026 and a focus on cost discipline, Cibus aims to fund its commercialization milestones while navigating regulatory hurdles in key markets.
What we're watching
- Regulatory Momentum
- The pace at which the European Parliament advances the New Genomic Techniques regulation will determine Cibus' ability to commercialize gene-edited crops in key markets.
- Market Expansion
- Whether Cibus can secure additional commercialization agreements in Brazil and Argentina will be critical to meeting its 2027 Latin American launch target.
- Execution Risk
- How Cibus manages the delayed U.S. launch of its herbicide-tolerant rice program will impact its ability to capture $200M in annual addressable royalties at peak.
Related topics